跳至主要内容
临床试验/NCT03896139
NCT03896139已完成不适用

Identification of PAthways of Kinase Inhibitors TOxicity Through Patient Databases

Groupe Hospitalier Pitie-Salpetriere1 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2017年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4,000
试验地点
1
主要终点
Comparison of the incidence of kinase inhibitor (KIs) induced toxicities in health records and their associations with co-medications to identify new mechanisms of drug induced toxicity

研究概览

简要总结

The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient treated with a kinase inhibitor
  • Patient identified in the VUMC EHR cohort or having a toxicity reported in the VigiBase

排除标准

  • 未提供

研究组 & 干预措施

VUMC EHR cohort

De-identified version of the electronic health record (EHR) at Vanderbilt University Medical Center (VUMC).

干预措施: Kinase inhibitor (Drug)

Toxicity induced by kinase inhibitors in Vigibase database

Case reported in the World Health Organization (WHO) of toxicity or complication of patient treated by KIs, with a chronology compatible with the drug toxicity

干预措施: Kinase inhibitor (Drug)

结局指标

主要结局

Comparison of the incidence of kinase inhibitor (KIs) induced toxicities in health records and their associations with co-medications to identify new mechanisms of drug induced toxicity

时间窗: population included in VUMC database and/or WHO's database resource up to march 2019

Identification of a mechanism of a toxicity associated with a KI using comedications and comparing it to reported outcomes

次要结局

未报告次要终点

研究者

发起方
Groupe Hospitalier Pitie-Salpetriere
申办方类型
Other
责任方
Principal Investigator
主要研究者

Joe Elie Salem

Investigator

Groupe Hospitalier Pitie-Salpetriere

研究点 (1)

Loading locations...

相似试验